FDA approves new multiple sclerosis treatment: Tecfidera

FDA approves new multiple sclerosis treatment: Tecfidera27 March 2013 Resd the press release
Source: BrainBlog - Category: Neurologists Source Type: blogs

Related Links:

Publication date: Available online 22 February 2020Source: SteroidsAuthor(s): Asadollah Mohammadi, Asaad Azarnezhad, Hashem Khanbabaei, Esmael Izadpanah, Rasoul Abdollahzadeh, George E. Barreto, Amirhossein SahebkarAbstractThere are conflicting results regarding the exact effect of the vitamin D receptor (VDR) gene polymorphisms on the susceptibility to multiple sclerosis (MS). Therefore, we aimed to investigate the impact of four major studied VDR gene polymorphisms consisting of ApaI, BsmI, FokI, and TaqI on the risk of MS in the Iranian population. A literature search was performed in various databases to find case-cont...
Source: Steroids - Category: Drugs & Pharmacology Source Type: research
Medicinal cannabinoid use continues to evolve across the United States, although legitimate federal recognition for medicinal purpose is lacking. Variability exists across states within the United States with respect to legislation, and health care institutions encounter challenges when patients present with a history of medicinal cannabinoid use. Emerging evidence in the field of neurosciences suggests a role of cannabinoids for neurologic medical conditions such as Parkinson disease, multiple sclerosis, and epilepsy. We aim to provide an overview of cannabinoids including a historical perspective, pharmacology, applicati...
Source: Critical Care Nursing Quarterly - Category: Nursing Tags: Original Articles Source Type: research
We report the first two patients, who underwent in vitro maturation protocol in order to avoid the exacerbation risk due to controlled ovarian stimulation at a large tertiary university hospital. Both patients were referred to our infertility clinic with the concern of multiple sclerosis exacerbation after or during controlled ovarian stimulation treatment. The patients underwent in vitro maturation protocol in order to avoid ovarian stimulating agents. Both patients gave birth to healthy babies at term. They did not suffer any multiple sclerosis relapses during their treatment and during pregnancy. Controlled ovarian stim...
Source: Reproductive BioMedicine Online - Category: Reproduction Medicine Source Type: research
Conclusion: SES and race may influence affective symptoms reported by individuals with MS. The reasons for the correlation are likely multifactorial. Longitudinal studies should strive to identify factors associated with risk of affective symptoms in MS that may be modifiable.
Source: Multiple Sclerosis and Related Disorders - Category: Neurology Source Type: research
Conclusion: Non-compliance to DMT recommendation in patients with MS in a Canadian practice is sizable, due to patients’ own perspectives of disease and their belief in alternative complementary medicine.
Source: Multiple Sclerosis and Related Disorders - Category: Neurology Source Type: research
ConclusionAtrophied T2-LV is associated with disability accrual in MS, and to several multimodal markers of disease evolution.
Source: Journal of Neurology - Category: Neurology Source Type: research
AbstractPatients with multiple sclerosis on long-term injectable therapies may suffer from the so-called “needle fatigue”, i.e., a waning commitment to continue with the prescribed injectable treatment. Therefore, alternative treatment strategies to enhance patients’ adherence are warranted. In this independent, multicentre post-marketing study, we sought to directly compare switching to either t eriflunomide (TFN), dimethyl fumarate (DMF), or pegylated interferon (PEG) on treatment persistence and time to first relapse over a 12-month follow-up. We analyzed a total of 621 patients who were free of relaps...
Source: Journal of Neurology - Category: Neurology Source Type: research
Condition:   Multiple Sclerosis, Relapsing-Remitting Interventions:   Other: Intermittent Hypoxia;   Other: Sham Hypoxia Sponsors:   Shirley Ryan AbilityLab;   Edward Hines Jr. VA Hospital Completed
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Multiple Sclerosis Intervention:   Device: Focused Ultrasound (MRgFUS) for the Management of Tremor in Patients With Multiple Sclerosis Sponsors:   Sunnybrook Health Sciences Centre;   Multiple Sclerosis Society of Canada Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Multiple Sclerosis, Relapsing-Remitting Interventions:   Other: Intermittent Hypoxia;   Other: Sham Hypoxia Sponsors:   Shirley Ryan AbilityLab;   Edward Hines Jr. VA Hospital Completed
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Multiple Sclerosis | Neurologists